icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TEZSPIRE (Tézépélumab).
Voir aussi
Décision d'accès précoce
22/12/2022
eNrlWN9v2jAQfu9fgfLuhFC6hClQbazdkFaN0aJNe0HGOcDMxKl/UNq/fg6hG52StTX1S/eCjM/57mzffXfn5HSzYo01CEl51vVCv+k1ICM8pdm8642vzlHsnfaOkiVe471lkd/0w5bXIAxL2fUKqT8FnEn/+8XnD2C+B+H1jhoJny6BqAfrtKLM/4Tl4gLnxZpGsuY0baxALXja9XKttrONRCphrOjdcPFT5phAEuxm9qXLSXt/PgkKsCegagniM87mlaAzYYVJtBCQqT5WMOfithI6F2k4aXXiN2EntlJC5Qgk14LAEKvFUPA1TSGt3gZmEqyUzG7SSxBrBqpQUgkeLMlKWoHjJd6M4HpQbfQ7I+2rjUJNFEZRMwzb7TDstCMrVWLvqKrdx2wiyCfHx524HUfBTAQpEFp4OcpazVYLNdtRHKQkkLBCqUbhCTILYDUVgLZyM0c4YzAHI0AMowXWCpD54YKq7aTEmRnkXCgzQAJmWu7WprDCmRmmCBMCEuXChA65R5K5MQWzAkXBncypAEuPGRa6mSNfobL/0O8d6RFw/ahPplTmDN/6S5nbHhUW2IhBGHZyt5FiB1fC8CUzZ/YXfqYZC55p9XjHZo4sLsiyz3WmakjtfGR7EH1uYmNTf6N2PKw2O1+kIF8O9o5n1TloqKeMEluiNVSoQarxaFDPs6+fot5jCWPhjqO+0SzlN/LluW/f1xxZv70XVg1KJq04OulE9lXQD+PWNbn4TAueQ2A4kcpDqG6QzfihJGcipRrqPk5eeYhsC1ZOMIOakhVZsrCJjfsK21n0uYvsUlAJ+vHsytZpv2oQt5fbv5XQNO3+dje7FOUi75kQqTX8+QFXss4/m5mSfdrxsV0ro0U1qS2UyuXbIFhgWYadbyL6/0iDe/WQu9bOSdFVFqFlMnFk+rSsEZ7uM7bh/1hJdmibsft+185U6lBCwwH3UGYKZ3w+OHv5FPGnx3Bm9vABpblTs+0HsDLc5Koi1NPq16WDkpK51+xcGHL4MpvRmve2Wr9MgvKtr3eUBMU7X+/oF3s1tvM=
ARYCgVsGKZB9qzXh